(Q54558691)

English

Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.

scientific article published in January 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21932373%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21932373%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

liver transplantation

1 reference

based on heuristic

inferred from title

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

recurrent hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21932373%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

author name string

Carlos Gomez-Martin

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21932373%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Javier Bustamante

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21932373%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Javier F Castroagudin

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21932373%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Magdalena Salcedo

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21932373%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Elena Garralda

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21932373%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Milagros Testillano

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21932373%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Ignacio Herrero

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21932373%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Ana Matilla

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21932373%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

publication date

1 January 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21932373%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Liver Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21932373%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21932373%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21932373%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

45-52

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21932373%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice

1 reference

https://api.crossref.org/works/10.1002%2FLT.22434

21 January 2018

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1002%2FLT.22434

21 January 2018

Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy

1 reference

https://api.crossref.org/works/10.1002%2FLT.22434

21 January 2018

The TOR pathway: a target for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FLT.22434

21 January 2018

Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FLT.22434

21 January 2018

Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FLT.22434

21 January 2018

De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects.

1 reference

https://api.crossref.org/works/10.1002%2FLT.22434

21 January 2018

Long-term survival after recurrent hepatocellular carcinoma in liver transplant patients: clinical patterns and outcome variables

1 reference

https://api.crossref.org/works/10.1002%2FLT.22434

21 January 2018

Management of hepatocellular carcinoma recurrence after liver transplantation.

1 reference

https://api.crossref.org/works/10.1002%2FLT.22434

21 January 2018

Prognostic factors for tumor recurrence after a 12-year, single-center experience of liver transplantations in patients with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FLT.22434

21 January 2018

Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FLT.22434

21 January 2018

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FLT.22434

21 January 2018

Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle.

1 reference

https://api.crossref.org/works/10.1002%2FLT.22434

21 January 2018

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo

1 reference

https://api.crossref.org/works/10.1002%2FLT.22434

21 January 2018

Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FLT.22434

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FLT.22434

21 January 2018

Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence

1 reference

https://api.crossref.org/works/10.1002%2FLT.22434

21 January 2018

Cyclosporine induces cancer progression by a cell-autonomous mechanism.

1 reference

https://api.crossref.org/works/10.1002%2FLT.22434

21 January 2018

Current and future directions in mammalian target of rapamycin inhibitors development

1 reference

https://api.crossref.org/works/10.1002%2FLT.22434

21 January 2018

Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1002%2FLT.22434

21 January 2018

Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression

1 reference

https://api.crossref.org/works/10.1002%2FLT.22434

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54558691&oldid=2076859067"